Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
AIDS Res Ther ; 21(1): 40, 2024 06 18.
Artículo en Inglés | MEDLINE | ID: mdl-38890671

RESUMEN

BACKGROUND: Scholars recommend providing migrants living with HIV (MLWH) with free treatment, rapidly, once linked to care to optimize their HIV-related experiences and health outcomes. Quantitative evaluations of patient-reported measures for MLWH in such models are necessary to explore the viability of these recommendations. METHODS: Within a 96-week prospective cohort study at a multidisciplinary HIV clinic, participants received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for free and rapidly following care linkage. Eight patient-reported measures were administered at weeks 4, 24, and 48: (1) mMOS-SS to measure perceived social support; (2) IA-RSS to measure internalized stigma; (3) K6 to measure psychological distress; (4) PROMIS to measure self-efficacy with treatment taking; (5) G-MISS to measure perceived compliance with clinicians' treatment plans; (6) HIVTSQ to measure treatment satisfaction; (7) CARE to measure perceived provider empathy; and (8) PRPCC to measure perceived clinician cultural competence. Linear mixed modelling with bootstrapping was conducted to identify significant differences by sociodemographics and time. RESULTS: Across weeks 4, 24, and 48, results suggest that MLWH enrolled in this study experienced moderate levels of social support; elevated levels of HIV-related stigma; moderate levels of distress; high self-efficacy with daily medication self-management; great compliance with clinicians' treatment plans; high treatment satisfaction; high perceived empathy; and high perceived cultural competence. Experience of social support (i.e., mMOS-SS scores) differed significantly by birth region. Experience of HIV-related stigma (i.e., IA-RSS scores) differed significantly by birth region, age, and language. Experience of distress (i.e., K6 scores) differed significantly by sexual orientation. Experience of treatment satisfaction (i.e., HIVTSQ scores) differed significantly by birth region and age. No significant differences were identified by time for any measure. CONCLUSION: Overall, participants expressed positive experiences around treatment and care, alongside comparably lower perceptions of social support, internalized stigma, and distress, potentially underscoring a need to embed targeted, well-funded, and accessible mental health support within HIV care models.


Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , Medición de Resultados Informados por el Paciente , Estigma Social , Migrantes , Humanos , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/psicología , Masculino , Femenino , Adulto , Estudios Prospectivos , Fármacos Anti-VIH/uso terapéutico , Persona de Mediana Edad , Apoyo Social , Compuestos Heterocíclicos de 4 o más Anillos/uso terapéutico , Tenofovir/uso terapéutico , Emtricitabina/uso terapéutico , Piperazinas/uso terapéutico , Cumplimiento de la Medicación , Piridonas/uso terapéutico , Combinación de Medicamentos , Satisfacción del Paciente , Adulto Joven , Autoeficacia , Amidas , Compuestos Heterocíclicos con 3 Anillos
2.
HIV Med ; 25(5): 600-607, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38213087

RESUMEN

OBJECTIVE: Multidisciplinary care with free, rapid, and on-site bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) dispensation may improve health outcomes among migrants living with HIV. However, models for rapid B/F/TAF initiation are not well studied among migrants living with HIV, and an understanding of how social determinants of health (SDH) may affect HIV-related health outcomes for migrants enrolled in such care models is limited. METHODS: Within a 96-week pilot feasibility prospective cohort study at a multidisciplinary HIV clinic, participants received free B/F/TAF rapidly after care linkage. The effects of SDH (i.e., birth region, sexual orientation, living status, education, employment, French proficiency, health coverage, use of a public health facility outside our clinic for free blood tests, and time in Canada) and other covariates (i.e., age, sex) on median time to antiretroviral therapy (ART) initiation and HIV viral undetectability from care linkage were calculated via survival analyses. RESULTS: Thirty-five migrants were enrolled in this study. Median time to ART initiation and HIV undetectability was 5 days (range 0-50) and 57 days (range 5-365), respectively. Those who took significantly longer to initiate ART were aged <35 years, identified as heterosexual, had less than university-level education, or were unemployed. No factor was found to significantly affect time to undetectability. CONCLUSION: Despite the provision of free B/F/TAF, several SDH were linked to delays in ART initiation. However, once initiated and engaged, migrants living with HIV reached HIV undetectability efficiently. Findings provide preliminary support for adopting this care model with migrants living with HIV and suggest that SDH should be considered when designing clinical interventions for more equitable outcomes.


Asunto(s)
Emtricitabina , Infecciones por VIH , Determinantes Sociales de la Salud , Tenofovir , Migrantes , Humanos , Infecciones por VIH/tratamiento farmacológico , Femenino , Masculino , Adulto , Estudios Prospectivos , Migrantes/estadística & datos numéricos , Tenofovir/uso terapéutico , Emtricitabina/uso terapéutico , Proyectos Piloto , Persona de Mediana Edad , Alanina/uso terapéutico , Alanina/análogos & derivados , Compuestos Heterocíclicos de 4 o más Anillos/uso terapéutico , Compuestos Heterocíclicos con 3 Anillos/uso terapéutico , Fármacos Anti-VIH/uso terapéutico , Tiempo de Tratamiento , Combinación de Medicamentos , Carga Viral , Estudios de Factibilidad , Adulto Joven , Canadá , Amidas , Piperazinas , Piridonas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA